Kenneth Cleveland, M.D. signs the paperwork that lets physicians practice in Mississippi. On 19 August 2026, his signature landed on a one-page statement, beside the executive directors of the nursing board and the pharmacy board, telling the state’s licensed providers to stop handling research-grade peptides at all: “under no circumstances.”
The person that page protects is the one already holding a vial, and the clinic that sold it to her is the one it embarrasses. Three state boards wrote down what the sales pages leave out.
The honest answer to “are peptides legal” splits by bottle. An FDA-approved peptide drug is legal in the United States with a valid prescription from a licensed prescriber. A research-grade or FDA-ineligible peptide is not legal for a licensed provider to compound, prescribe, dispense or recommend in Alabama, Mississippi and South Carolina, and those three boards each put that in writing between 26 May and 19 August 2026.
The Short Answer – The Bottle Decides, Not the Molecule
Federal law draws one line, and FDA explains it on its own compounding page. A state-licensed physician or pharmacist may compound with a bulk substance only if it complies with a USP or NF monograph, or is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list.
A research vial of BPC-157 or TB-500 clears none of the three. FDA says as much on the safety page it dates 22 April 2026, where BPC-157 carries the line that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans.”
A state board does not need a new statute to act on that. It needs a licensee, a standard of care and a letter.
Alabama – Are Peptides Legal? The Formulary Already Said No
The Alabama Board of Medical Examiners issued its notice on 26 May 2026, and Reuters carried it the same day. The operative sentence: “under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient.”
The second half of the notice shuts the nurse-practitioner route with a piece of machinery patients rarely hear about. Alabama allows a CRNP, CNM or PA to prescribe only from a formulary the medical and nursing boards approve jointly, and the board’s finding is flat: “No research grade or non-FDA approved peptide is included on any approved formulary.”
Consent does not fix it. The board calls consent forms that label a product “research-grade” ineffective.
A formulary is a short list. Nothing had to be added to it for the answer to come back no.
Mississippi – Three Boards, Three Signatures, One Date
Mississippi went further than a single board. The Board of Nursing, the Board of Pharmacy and the State Board of Medical Licensure signed a joint statement on 19 August 2026, and the sentence they chose has no conditional in it: “Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide to a patient.”
The statement then closes two doors that peptide sellers have leaned on for years. The first is delegation, because a physician may not pass the job to a nurse or a colleague: “A healthcare provider may not circumvent his or her duty of care to patients by permitting or delegating the purchase, administration, or dispensing of these drugs to other providers.” The second is paperwork, because consent forms identifying a product as research-grade “do not mitigate or eliminate a provider’s professional or legal liability.”
Mississippi also told the patient exactly where she stands if she bought the vial herself. Self-administration carries risk that “rests solely with the patient,” and any licensed professional who advises, recommends, supplies, prescribes or administers the same product is practicing medicine outside the law.
The three signatories are Kenneth Cleveland, M.D., Phyllis Polk Johnson, DNP, APRN, and Susan McCoy, R.Ph. Getting a nursing board, a pharmacy board and a medical board onto one page is hard enough that the American Pharmacists Association wrote it up as a milestone. A waiver form is no match for it.
South Carolina – Are Peptides Legal? The Salt Form Gave It Away
The South Carolina Board of Medical Examiners posted a notice with the same teeth, and the text carries no printed date. The American Med Spa Association flagged it on 18 August 2026.
South Carolina named the product category most clinics are selling. its text notes that “peptides (including semaglutide) are being advertised to physician offices and the public for purchase from innumerable sources, some of which are not permitted by the South Carolina Board of Pharmacy.”
Then a footnote lands on the vial itself. Facilities are selling “semaglutide salt forms and research grade powder,” and the board limits legal compounding to prescription-quality powder.
FDA reached the same place in its own words. Semaglutide sodium and semaglutide acetate “are different active ingredients” from the drug in the approved product, the agency writes, and it adds that it is “not aware of any lawful basis for their use in compounding.” A salt on a label is a different molecule from the one in the approved pen, so the box and the syringe describe two different things.
South Carolina also made buying the supply a licensure matter. A practitioner who purchases drug components from a facility without a pharmacy permit is “aiding and abetting unlicensed practice” and can be disciplined for unprofessional conduct. The investigation can start at the prescriber and end at the vendor.
The FDA – The List That Has Not Grown Since 2019
FDA’s position on compounded products is stated in one plain line on its GLP-1 page: compounded drugs are not FDA approved, which means “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”
The same page carries a number that no marketing site publishes. As of 31 May 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and the agency notes that federal law does not require state-licensed pharmacies to report those events, so the count is a floor.
FDA also states that retatrutide and cagrilintide cannot be used in compounding under federal law, and that neither is a component of an approved drug.
The July story that travelled furthest was the advisory committee meeting. FDA convened its Pharmacy Compounding Advisory Committee on 23 and 24 July 2026 to review seven peptides for the 503A bulks list, and the meeting notice sits in the Federal Register under Docket FDA-2025-N-6895. FDA’s own meeting page describes what those votes are worth: the committee makes “non-binding recommendations to the FDA.”
The list itself is the measurement that counts, and it has not moved. FDA placed six substances on the 503A bulks list in a final rule published 19 February 2019, proposed an amendment in September 2019, and a Federal Register search for 2019 through 2026 returns no later rule amending that list. A recommendation is a signal. A rule is the thing that changes what a pharmacy may put in a vial.
What This Means If You Already Have Vials in the Fridge
Start with the pharmacy permit, because that is the question a board investigator asks first. State pharmacy boards run license lookups, and the South Carolina notice links its own; Mississippi publishes one as well. A seller that cannot be found in a state’s lookup is not a pharmacy in that state.
Then ask two questions of whoever sold you the product. Is the active ingredient on FDA’s 503A bulks list, and can they show you where. Is the ingredient pharmaceutical grade, or does the certificate describe material labeled for research use.
Then handle the vial by FDA’s rule rather than the seller’s. For a multidose sterile vial, FDA recommends discarding it within 28 days of the first use, even with medication still inside, because contamination risk climbs after that. The agency also reports hospitalizations from dosing errors with compounded injectable semaglutide, where patients measured or clinics calculated the wrong amount.
None of this is a reason to panic about a prescription for an approved peptide drug. It is a reason to check which of the two things you are holding, because only one of them comes with a government-reviewed label and a liability trail.
Frequently asked questions
Are peptides legal to buy online?
It depends on the peptide and the seller. FDA-approved peptides need a prescription from a licensed prescriber, filled by a state-licensed pharmacy. A vial sold to a consumer without that pathway is an unapproved drug, whatever the label calls it, and three state boards now bar licensed providers from supplying those products to patients at all.
Are peptides legal in my state?
Federal law sets the floor, so the federal answer holds in all fifty states. Enforcement varies, and 2026 added Alabama, Mississippi and South Carolina to the list of states whose boards have published peptide notices. Boards in other states have not made a public statement yet, which is not the same as permission.
Are peptides legal with a prescription?
For an FDA-approved peptide drug, a valid prescription from a licensed prescriber is the legal pathway, and state medical and pharmacy rules govern how that prescription is written and filled. For a research-grade peptide, the boards in Alabama, Mississippi and South Carolina say a prescription does not create a lawful pathway, even with a signed consent form.
Are compounded peptides FDA-approved?
No. FDA states that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before marketing. A compounded product also is not the same article as the approved drug it copies, which is the whole point of the salt-form warning FDA published about semaglutide sodium and semaglutide acetate.
Did the July 2026 FDA committee vote make peptides legal?
No. The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and makes non-binding recommendations. Adding a substance to the 503A bulks list takes notice-and-comment rulemaking, and no rule amending that list has been published since the February 2019 final rule.
How do I check whether my peptide came from a licensed pharmacy?
Use your state pharmacy board’s license lookup, not the seller’s website. Ask for the permit number and the state that issued it, then verify it. Ask the clinic for the pharmacy’s name as it appears on the vial label. A label that names a pharmacy you cannot find in a state lookup is the single strongest warning sign in this market.
Sources: FDA – Concerns with unapproved GLP-1 drugs used for weight loss | FDA – Certain bulk drug substances that may present significant safety risks | FDA – Bulk drug substances used in compounding under section 503A | FDA – Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026 | Alabama Board of Medical Examiners notice, 26 May 2026 | Mississippi joint statement, 19 August 2026 | South Carolina Board of Medical Examiners notice | Federal Register – final rule adding six substances to the 503A bulks list, 19 February 2019